Global Markets Direct's latest Pharmaceutical
and Healthcare disease pipeline guide Diabetic
Retinopathy - Pipeline Review, H1 2018, provides an overview of the
Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.
Diabetic
retinopathy is a complication of diabetes that affects the eyes. Diabetic
retinopathy symptoms may include spots or dark strings floating in vision
(floaters), blurred vision, fluctuating vision, vision loss and difficulty with
color perception. The predisposing factors include diabetes, high blood
pressure, high cholesterol, pregnancy and tobacco use. Global Markets Direct's
Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy -
Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Diabetic Retinopathy (Metabolic Disorders),
complete with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Diabetic
Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players
involved in therapeutic development for Diabetic Retinopathy and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules developed by
Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown
stages are 4, 9, 7, 47, 12 and 1 respectively. Similarly, the Universities
portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules,
respectively. Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built using data
and information sourced from Global Markets Direct's proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
The pipeline
guide provides a snapshot of the global therapeutic landscape of Diabetic
Retinopathy (Metabolic Disorders). The pipeline guide reviews pipeline
therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and
universities/research institutes based on information derived from company and
industry-specific sources. The pipeline guide covers pipeline products based on
several stages of development ranging from pre-registration till discovery and
undisclosed stages. The pipeline guide features descriptive drug profiles for
the pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities. The pipeline guide reviews key companies involved in
Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their
major and minor projects.
The pipeline
guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based
on mechanism of action (MoA), drug target, route of administration (RoA) and
molecule type. The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. The pipeline guide reviews latest news related to pipeline
therapeutics for Diabetic Retinopathy (Metabolic Disorders). Procure
strategically important competitor information, analysis, and insights to
formulate effective R&D strategies. Recognize emerging players with
potentially strong product portfolio and create effective counter-strategies to
gain competitive advantage. Find and recognize significant and varied types of
therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
Classify potential new clients or partners in the target demographic.
Develop
tactical initiatives by understanding the focus areas of leading companies. Plan
mergers and acquisitions meritoriously by identifying key players and it's most
promising pipeline therapeutics. Formulate corrective measures for pipeline
projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline
depth and focus of Indication therapeutics. Develop and design in-licensing and
out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope. Adjust
the therapeutic portfolio by recognizing discontinued projects and understand
from the know-how what drove them from pipeline.
For more information on the research report,
refer to below link:
Related Reports:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
